GW823093C For The Treatment Of Type 2 Diabetes Mellitus

Phase 2

Terminated

• Conditions: Diabetes Mellitus, Type 2
• Interventions: Drug: GW823093C A; Drug: GW823093C B; Drug: GW823093C C

• Registration Number: NCT00370942
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This study was designed to find dose response and as extension in treatment of GW823093C.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-04-01
• Study First Submitted: 2006-08-30
• Study First Submitted QC: 2006-08-30
• Study First Posted: 2006-09-01
• Primary Completion: 2006-11-01
• Study Completion: 2006-11-25
• Status Verified: 2018-08
• Last Update Submitted: 2018-08-30
• Last Update Posted: 2018-08-31

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 159

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
GW823093C A	GW823093C A	A=45 mg
GW823093C B	GW823093C B	B=30 mg
GW823093C C	GW823093C C	C=15 mg

Primary Outcome Measures

Name	Time	Method
Efficacy variables Dose response (change from baseline in HbA1c) at stipulated date in each treatment group	12 weeks

Secondary Outcome Measures

Name	Time	Method
Long term safety variables	64 weeks

Trial Locations

Locations (1)

GSK Investigational Site